Recursion Pharmaceuticals has recently received FDA clearance to begin clinical trials for REC-1245, a promising drug designed to treat biomarker-enriched solid tumors and lymphomas.

This first-in-class candidate targets RBM39, a protein involved in tumor cell proliferation. The approval to move forward with trials marks a significant milestone for Recursion’s AI-driven drug discovery platform.

REC-1245 was discovered using Recursion’s cutting-edge artificial intelligence technology, which allowed the company to accelerate drug development.

The AI-driven approach enabled Recursion to analyze vast amounts of biological data and identify promising molecular targets faster than traditional methods.

With this breakthrough, Recursion aims to reduce the timeline and costs associated with bringing new cancer treatments to market.

The initial clinical trial will assess the drug’s safety, efficacy, and its potential as a monotherapy for difficult-to-treat cancers.

If successful, this could offer new treatment options for patients with solid tumors that have limited therapeutic alternatives.